These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 9264493)

  • 1. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group.
    Cohn JN; Ziesche S; Smith R; Anand I; Dunkman WB; Loeb H; Cintron G; Boden W; Baruch L; Rochin P; Loss L
    Circulation; 1997 Aug; 96(3):856-63. PubMed ID: 9264493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale and design of the third vasodilator-heart failure trial (V-HeFT III): felodipine as adjunctive therapy to enalapril and loop diuretics with or without digoxin in chronic congestive heart failure. V-HeFT III investigators.
    Boden WE; Ziesche S; Carson PE; Conrad CH; Syat D; Cohn JN
    Am J Cardiol; 1996 May; 77(12):1078-82. PubMed ID: 8644661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of effects on peak oxygen consumption, quality of life, and neurohormones of felodipine and enalapril in patients with congestive heart failure.
    de Vries RJ; Queré M; Lok DJ; Sijbring P; Bucx JJ; van Veldhuisen DJ; Dunselman PH
    Am J Cardiol; 1995 Dec; 76(17):1253-8. PubMed ID: 7503006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vasodilators in heart failure. Conclusions from V-HeFT II and rationale for V-HeFT III.
    Cohn JN
    Drugs; 1994; 47 Suppl 4():47-57; discussion 57-8. PubMed ID: 7523062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group.
    Carson P; Ziesche S; Johnson G; Cohn JN
    J Card Fail; 1999 Sep; 5(3):178-87. PubMed ID: 10496190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma norepinephrine and atrial natriuretic peptide in heart failure: influence of felodipine in the third Vasodilator Heart Failure Trial. V-HeFT III investigators.
    Smith RF; Germanson T; Judd D; Wong M; Ziesche S; Anand IS; Taylor WR; Cohn JN
    J Card Fail; 2000 Jun; 6(2):97-107. PubMed ID: 10908083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Felodipine improves left ventricular emptying in patients with chronic heart failure: V-HeFT III echocardiographic substudy of multicenter reproducibility and detecting functional change.
    Wong M; Germanson T; Taylor WR; Cohen IS; Perry G; Baruch L; Deedwania P; Lopez B; Cohn JN
    J Card Fail; 2000 Mar; 6(1):19-28. PubMed ID: 10746815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mild systolic dysfunction in heart failure (left ventricular ejection fraction >35%): baseline characteristics, prognosis and response to therapy in the Vasodilator in Heart Failure Trials (V-HeFT).
    Carson P; Johnson G; Fletcher R; Cohn J
    J Am Coll Cardiol; 1996 Mar; 27(3):642-9. PubMed ID: 8606276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Placebo controlled trial of felodipine in patients with mild to moderate heart failure. UK Study Group.
    Littler WA; Sheridan DJ
    Br Heart J; 1995 May; 73(5):428-33. PubMed ID: 7786657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The Losartan Pilot Exercise Study Investigators.
    Lang RM; Elkayam U; Yellen LG; Krauss D; McKelvie RS; Vaughan DE; Ney DE; Makris L; Chang PI
    J Am Coll Cardiol; 1997 Oct; 30(4):983-91. PubMed ID: 9316528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vasodilation by urapidil in the treatment of chronic congestive heart failure in addition to angiotensin-converting enzyme inhibitors is not beneficial: results of a placebo-controlled, double-blind study.
    Dorszewski A; Göhmann E; Dorsźewski B; Werner GS; Kreuzer H; Figulla HR
    J Card Fail; 1997 Jun; 3(2):91-6. PubMed ID: 9220308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group.
    Baruch L; Anand I; Cohen IS; Ziesche S; Judd D; Cohn JN
    Circulation; 1999 May; 99(20):2658-64. PubMed ID: 10338459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different results in cardiopulmonary exercise tests after long-term treatment with felodipine and enalapril in patients with congestive heart failure due to ischaemic heart disease.
    Dunselman PH; van der Mark TW; Kuntze CE; van Bruggen A; Hamer JP; Scaf AH; Wesseling H; Lie KI
    Eur Heart J; 1990 Mar; 11(3):200-6. PubMed ID: 2318222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved efficacy with maintained tolerability in the treatment of primary hypertension. Comparison between the felodipine-metoprolol combination tablet and monotherapy with enalapril. Swedish Multicentre Group.
    Andersson OK
    J Hum Hypertens; 1999 Jan; 13(1):55-60. PubMed ID: 9928753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydralazine and isosorbide dinitrate combination improves exercise tolerance in heart failure. Results from V-HeFT I and V-HeFT II. The V-HeFT VA Cooperative Studies Group.
    Ziesche S; Cobb FR; Cohn JN; Johnson G; Tristani F
    Circulation; 1993 Jun; 87(6 Suppl):VI56-64. PubMed ID: 8500241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The calcium channel blocker felodipine attenuates the positive hemodynamic effects of the beta-blocker metoprolol in severe dilated cardiomyopathy--a prospective, randomized, double-blind and placebo-controlled study with invasive hemodynamic assessment.
    Braun M; Edelmann F; Knapp M; Schön S; Schwencke C; Simonis G; Borst M; Weinbrenner C; Strasser RH
    Int J Cardiol; 2009 Feb; 132(2):248-56. PubMed ID: 18579230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study.
    Packer M; Gheorghiade M; Young JB; Costantini PJ; Adams KF; Cody RJ; Smith LK; Van Voorhees L; Gourley LA; Jolly MK
    N Engl J Med; 1993 Jul; 329(1):1-7. PubMed ID: 8505940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Felodipine-metoprolol combination tablet: a valuable option to initiate antihypertensive therapy?
    Waeber B; Detry JM; Dahlöf B; Puig JG; Gundersen T; Hosie J; Januszewicz W; Lindström CJ; Magometschnigg D; Safar M; Tanser P; Toutouzas P
    Am J Hypertens; 1999 Sep; 12(9 Pt 1):915-20. PubMed ID: 10509550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. The V-HeFT VA Cooperative Studies Group.
    Loeb HS; Johnson G; Henrick A; Smith R; Wilson J; Cremo R; Cohn JN
    Circulation; 1993 Jun; 87(6 Suppl):VI78-87. PubMed ID: 8500244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lessons from V-HeFT: questions for V-HeFT II and the future therapy of heart failure.
    Cohn JN
    Herz; 1991 Sep; 16 Spec No 1():267-71. PubMed ID: 1820292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.